Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FlutiForm 250/10 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | FlutiForm 250/10ug |
| 2 | ACTIVE_COMPARATOR | SKP Fluticasone 250ug |
| 3 | ACTIVE_COMPARATOR | Flovent Fluticasone HFA |
| Name | Type | Description |
|---|---|---|
| FlutiForm 250/10 | DRUG | SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks. |
| SKP-Fluticasone | DRUG | SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks. |
| Flovent Fluticasone HFA | DRUG | Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks. |
Main Inclusion Criteria: * ≥ Age 12 years at the Screening Visit. * History of asthma for 12 months prior to the Screening Visit. * Documented use of an inhaled corticosteroid for at least 4 weeks prior to the Screening Visit. * Steroid-requiring patient * patients must demonstrate (1) an FEV1 of 4...
FlutiForm 250/10 is an investigational small molecule being developed for the treatment of asthma. It is a combination product containing fluticasone and formoterol, intended for use in adolescents and adults with moderate to severe asthma. The drug is currently in Phase 3 clinical development.
FlutiForm 250/10 combines fluticasone, a corticosteroid, and formoterol, a long-acting beta-agonist. Fluticasone reduces airway inflammation, while formoterol relaxes bronchial smooth muscle to improve airflow. This dual mechanism addresses both the inflammatory and bronchoconstrictive components of asthma.
FlutiForm 250/10 is being developed by Abbott Laboratories, a company publicly traded under the ticker symbol ABT. The drug is currently in Phase 3 clinical development for the treatment of asthma.
FlutiForm 250/10 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 clinical trial has been completed to evaluate its safety and efficacy in patients with moderate to severe asthma.
FlutiForm 250/10 has one completed Phase 3 clinical trial, identified as NCT00649025. This randomized, double-blind, active-controlled study enrolled 438 participants with moderate to severe asthma across multiple countries, including the United States, Argentina, Chile, Hungary, Mexico, Peru, Poland, Romania, South Africa, and Ukraine.
Yes, FlutiForm 250/10 is a combination product containing fluticasone and formoterol. It is being developed as a fixed-dose combination for the treatment of asthma. The drug is currently in Phase 3 clinical development and is not yet approved.